ProQR Restructures After Clinical Trial Setback, Impacting IRD Programs
News from the biotech sector often carries significant weight for the inherited retinal disease (IRD) community, as the development of new therapies offers hope for many. Recently, ProQR Therapeutics, a company focused on RNA therapies for genetic eye diseases, announced a significant restructuring following an unexpected clinical trial outcome. This news directly impacts ongoing and future research efforts for several IRDs, prompting a closer look at what this means for patients and families.
According to BioSpace, ProQR will be reducing its workforce by approximately 30% and its Chief Scientific Officer will be departing. This restructuring comes after the Phase II/III clinical trial for sepofarsen, a treatment for CEP290-mediated Leber congenital amaurosis 10 (LCA10), did not meet its primary and secondary endpoints in February. While earlier Phase I/II trials had shown vision improvements, the later-stage data did not detect significant improvement in patient vision.
As a direct consequence of the trial results and the subsequent restructuring, ProQR is suspending the development of two other assets: QR-1123, which was being developed for autosomal dominant retinitis pigmentosa, and QR-504a, intended for Fuchs endothelial corneal dystrophy. The company will also suspend all other IRD-related research activities. However, ProQR will continue to focus on its ultevursen (QR-421a) program for USH2A-mediated Usher syndrome and retinitis pigmentosa, with a single Phase 2/3 Sirius trial moving forward.
For patients and families affected by IRDs, news of trial failures and program suspensions can be disheartening. The discontinuation of QR-1123 for autosomal dominant retinitis pigmentosa and the broader halt on other IRD research means that potential treatment avenues for these specific conditions are currently on hold at ProQR. However, the company's commitment to the ultevursen program for Usher syndrome and retinitis pigmentosa offers a continued path forward for those affected by USH2A mutations. ProQR has indicated that these changes are designed to help fund essential programs into 2025.
ProQR plans to meet with regulatory authorities in the third quarter to discuss the data from the sepofarsen trial. While no new trials for sepofarsen are planned at this time, the company will accelerate the development of its Axiomer RNA base-editing technology platform, with initial efforts expanding into areas beyond the eye, such as liver and central nervous system diseases. This strategic shift highlights the dynamic nature of drug development and the continuous pursuit of scientific innovation.